[HTML][HTML] Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso, A Biroccio… - Journal of Experimental & …, 2018 - Springer
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
[HTML][HTML] Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso… - … of Experimental & …, 2018 - jeccr.biomedcentral.com
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
[HTML][HTML] Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso, A Biroccio… - … of Experimental & …, 2018 - ncbi.nlm.nih.gov
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso, A Biroccio… - Journal of Experimental …, 2018 - go.gale.com
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
[引用][C] Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso, A Biroccio… - Journal of Experimental …, 2018 - cir.nii.ac.jp
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
M Porru, L Pompili, C Caruso, A Biroccio… - … of Experimental & …, 2018 - europepmc.org
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso… - … of experimental & …, 2018 - pubmed.ncbi.nlm.nih.gov
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
M Porru, L Pompili, C Caruso… - … of Experimental & …, 2018 - search.ebscohost.com
Developing drugs that target < italic> KRAS</italic>, the most frequently mutated
oncogene in cancer, has not been successful despite much concerted efforts dedicated …
oncogene in cancer, has not been successful despite much concerted efforts dedicated …
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
M Porru, L Pompili, C Caruso, A Biroccio… - … of Experimental & …, 2018 - europepmc.org
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …
[HTML][HTML] Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
M Porru, L Pompili, C Caruso… - … of Experimental & …, 2018 - jeccr.biomedcentral.com
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …
not been successful despite much concerted efforts dedicated towards it in the last thirty …